- BioLife Solutions press release ( NASDAQ: BLFS ): Q2 GAAP EPS of -$1.71 misses by $1.50 .
- Revenue of $40.5M (+29.8% Y/Y) beats by $1.33M .
- Cell Processing platform: $67.0 million to $69.5 million, an increase of 49% to 55% over 2021 and organic growth of 42% to 47%. This includes biopreservation media and Sexton products.
- Freezers and Thaw Systems platform: $70.0 million to $71.5 million, an increase of 24% to 26% over 2021 and organic growth of 31% to 34%. COVID-19 related revenue is expected to account for less than 5% of the freezer and thaw systems platform revenue in 2022. This includes ThawStar thawing devices, cryogenic liquid nitrogen freezers and ULT Stirling freezers.
- Storage and Storage Services platform: $23.0 million to $25.0 million, a total and organic increase of 31% to 42% over 2021. COVID-19 related revenue is expected to account for approximately 41% to 45% of the storage and storage services platform revenue. COVID-19 related storage revenue is primarily generated from contracts, including contracts that extend beyond 2022.
For further details see:
BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M